Current Development Stage: Pre-Clinical
CARB-X Investment: Initial investment of up to $2.48m with potential option payments up to $3.76m. Additional $4.6m awarded June 2020 to support further development of Amicidin-β and development of extended formulation.
Initial CARB-X Investment Date: October 1, 2017
Location: United States, California, Carlsbad
Member count: 1-10
Investors 1
| Date | Name | Website |
| - | CARB-X | carb-x.org |